Steve Duffy

Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.

The patch was approved in March 2022 based on a relative bioavailability study in healthy patients comparing the transdermal system to Aricept tablets.

The device gained FDA approval in 2019 based on data from a placebo-controlled clinical trial that included 62 children with moderate to severe ADHD.

Brightly colored versions of the synthetic opioid fentanyl are appearing across the US, according to the Drug Enforcement Administration.

Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.

The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.

Nourianz is now available as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.

A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.

A recent review published in The Journal of Clinical Pharmacology discusses the antidiarrheal medication loperamide and its potential for abuse in patients looking to self-treat opioid withdrawal symptoms or to experience euphoric effects with large doses.

According to the results of a random-effects meta-analysis, there is a small, but significant, amount of evidence that supports the use of probiotics in the treatment of depression and anxiety.

A recent study published in the New England Journal of Medicine assessed the risk of new-onset psychosis among adolescents and young adults with attention deficit hyperactivity disorder (ADHD) initiated on various stimulant medications.